Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mapping of class II HLA restriction of SepSecS-specific CD4 T cell epitopes in autoimmune hepatitis.

JHEP reports : innovation in hepatology·2026
Same author

Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.

The Lancet. Haematology·2026
Same author

Analysis of infectious complications in paediatric autoimmune neutropenia: a French nationwide retrospective cohort study.

Archives of disease in childhood·2026
Same author

Securing raw materials, reagents, and consumable supplies in the academic bioproduction UNITC network: because the chain is only as strong as its weakest link.

Bone marrow transplantation·2025
Same author

Evaluation of multi-antigen targeting ADCC strategies in pediatric BCP-ALL.

Journal for immunotherapy of cancer·2025
Same author

NEOSKID study: Four years of experience in newborn screening for severe combined immunodeficiencies in the Pays de la Loire region of France.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2025

Related Experiment Video

Updated: Jul 9, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K

[Can academic structures improve access to CAR-T cells?]

Camille Le Guen1, Audrey Grain2, Baptiste Le Calvez3

  • 1Unité de thérapie cellulaire et génique, CHU de Nantes, 44093 Nantes, France.

Bulletin Du Cancer
|November 29, 2023
PubMed
Summary

Academic structures in France can improve access to chimeric antigen receptor T lymphocytes (CAR-T cells) by overcoming economic and ecological challenges in their production. This involves establishing feasible CAR-T cell manufacturing processes within academic settings.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology
Keywords:
AccessibilityAccessibilitéClinical trialDevelopmentDéveloppementEssai cliniqueEx-vivo gene therapyInnovationRegulationRéglementationThérapie génique ex vivo

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

933

Related Experiment Videos

Last Updated: Jul 9, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

933